SGLT-2i and GLP-1RA Combination Therapy Reduces Adverse Cardiovascular Events

admin

Combining sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy is associated with a lower incidence of cardiovascular events in patients with type 2 diabetes and a recent acute myocardial infarction. The study found that the combination therapy had a reduced incidence of major adverse cardiovascular events compared to either therapy alone. The researchers conducted a multicenter, prospective observational study and found that the combination therapy group had a lower incidence of cardiovascular events and better myocardial salvage index values compared to the groups receiving individual therapies. However, the study had limitations, including an observational design and inadequate sample sizes for subgroup analyses.

Source link

error: Content is protected !!